I only skimmed the 10q, basically just looking for
terms of the sharing agreement with Solexa. And of
course the terms are [*].
The ISB owes them a lousy $30k, I don't think they
are making much from them right now. You know
that Hood sits on Lynx, Lynx has somebody on
Solexa, Solexa has ties all over, and somehow
you can trace everything back to Kevin Bacon.
But clearly, when I made my descision to buy,
I had become convinced that MPSS is for real,
a very useful genomics tool, and the very low
marketcap (which was closer to 15 or 20M when
I bought them last week) makes Lynx a good
target. My not so witty banter on the Yahoo
board suggested Incyte or Curagen, but I was
just on the Yahoo board just now wondering if
they might saddle up with Solexa somehow.
Managment at Solexa looks a lot stronger
than the managment of Lynx. Understatement of
the year.
The confernce call last week sounded almost
recklessly enthusiastic about the technology.
About halfway through an obviously disgruntled
shareholder asked about revenue and such and
got a big screw you from KC. But I have to
agree, the revenue and such is the least
interesting thing to me.
I'm not taken in by the pharmacogenomics hype,
or the $1000 genome. But I think I do understand
what really matters, genomics applications by
hard core scientists. My notes are very sloppy:
Cluster tech--biological sample prep! Phenotype.
Reagent cost. Services market, MPSS instrumentation
plus proprietary reagents. Axaron.
Cluster into MPSS 3Q '05, operational 1/2 '06,
Early '07 sales.
Gene expression+epigenomics, genome resequencing,
genome structure.
NCI chromosomal config, genome frag, epigenomics,
with cluster tech dramatically less cost of
reagents. Biomarkers. Howard Hugues--Drosophilla
transcriptome. Ludwig--extension. PNAS colon.
Mouse transcriptome/reference.
RICE ".
Wellington--had two questions, they
must not have been worth writing down.
One smart fella (maybe it was augga?)
asked somethign about Dye singature.
I felt it was worth writing this bold:
WHOLE GENOME ASSEMBLY
Short reads, shotgun.
full length transcripts
gene--variant genes
To the private investor, no answer.
"We appreciate the question...Thank You."
No new Q2 guidance.
Funding strategy, new stock,
"future shareholders"
"new and existing shareholders"
sorry about the fragments.
I may listen to the call some
time to assemble the full transcript
(I already used that little gem over
on Yahoo. I don't think they like me
over there. TylerMath ran away, and
isn't saying much now. He is the teevee
guy, right?)
Anyway, the biology of Genomes thing was
this weekend. You probably noticed the
key speakers. Maybe I deluded myself into
thinking that Lynx will be bought out in
the next month, and the 20M...15M...12M
marketcap makes for a good speculation.
Disclaimer, full disclosure for any newbies
who might trip my little blog here:
I keep mentioning Texas holdem, where you
put your chips all-in. I did that with
Ariad a few years ago, it was awful and
wonderful. That $30k speculation, blossomed
into a secure retirement through the biotech
boom of late '99 and early '00, as you know.
I put ~$25k in Lynx this time, but as a
percentage of my net worth, it is ~2% rather
than the Ariad bet, which was, geeze, at the
time like 10% of my worth. I suggested to a
fellow at work that he could buy 1000 shares,
but that he should be ready to lose all his
money. That should give any new lurkers
something to measure me by.
You've met me so you know I'm just an average
joe who is dazzled by biotechnology and likes
to gamble a bit. Anybody who has read much on
this thread knows that I'm not in the same class
as the main biotech guys here on SI, and I would
hate it if anybody bought lynx, watched it go
to zero, and felt snookered in by my enthusiasm. |
